Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy

Detalhes bibliográficos
Autor(a) principal: Da-silva, V.a.
Data de Publicação: 1999
Outros Autores: Altenburg, S.p., Malheiros, L.r., Thomaz, T.g., Lindsey, Charles Julian [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/S0100-879X1999000100014
http://repositorio.unifesp.br/handle/11600/714
Resumo: The aim of the present study was to compare the toxic effects of fluoxetine (F) (8 and 16 mg/kg) and venlafaxine (V) (40 and 80 mg/kg) administered during the third week of pregnancy on early development of rats. Both antidepressants were administered by gavage on pregnancy days 15 to 20 to groups of 10 to 12 animals each. Duration of gestation, food and water consumption, number of live pups and birth weight were recorded. Litters were culled to six pups at birth (day 1) and followed for growth until weaning (day 25). On day 60, a male and a female from each litter were injected with the 5-HT1 agonist, 5-methoxy-N,N-dimethyltryptamine (6 mg/kg, ip) and the serotonergic syndrome was graded. Fluoxetine but not venlafaxine reduced the duration of pregnancy when compared to the control (C) group (F = 21.1 days and C = 21.6 days, mean, P<0.02; maximum = 22 days and minimum = 21 days in both groups). The highest doses of both fluoxetine, 16 mg/kg (F16), and venlafaxine, 80 mg/kg (V80), reduced the food intake of pregnant rats, resulting in different rates of body weight gain during treatment (from pregnancy day 15 to day 20): F16 = 29.0 g, V80 = 28.7 g vs C = 39.5 g (median). Birth weight was influenced by treatment and sex (P<0.05; two-way ANOVA). Both doses of fluoxetine or venlafaxine reduced the body weight of litters; however, the body weight of litters from treated dams was equal to the weight of control litters by the time of weaning. At weaning there was no significant difference in weight between sexes. There was no difference among groups in number of live pups at birth, stillbirths, mortality during the lactation period or in the manifestation of serotonergic syndrome in adult rats. The occurrence of low birth weight among pups born to dams which did not show reduced food ingestion or reduction of body weight gain during treatment with lower doses of fluoxetine or venlafaxine suggests that these drugs may have a deleterious effect on prenatal development when administered during pregnancy. In addition, fluoxetine slightly but significantly affected the duration of pregnancy (about half a day), an effect not observed in the venlafaxine-treated groups.
id UFSP_7b796a866c38e32b470b6c49226d5c05
oai_identifier_str oai:repositorio.unifesp.br/:11600/714
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancydevelopmentfluoxetinevenlafaxineratsThe aim of the present study was to compare the toxic effects of fluoxetine (F) (8 and 16 mg/kg) and venlafaxine (V) (40 and 80 mg/kg) administered during the third week of pregnancy on early development of rats. Both antidepressants were administered by gavage on pregnancy days 15 to 20 to groups of 10 to 12 animals each. Duration of gestation, food and water consumption, number of live pups and birth weight were recorded. Litters were culled to six pups at birth (day 1) and followed for growth until weaning (day 25). On day 60, a male and a female from each litter were injected with the 5-HT1 agonist, 5-methoxy-N,N-dimethyltryptamine (6 mg/kg, ip) and the serotonergic syndrome was graded. Fluoxetine but not venlafaxine reduced the duration of pregnancy when compared to the control (C) group (F = 21.1 days and C = 21.6 days, mean, P<0.02; maximum = 22 days and minimum = 21 days in both groups). The highest doses of both fluoxetine, 16 mg/kg (F16), and venlafaxine, 80 mg/kg (V80), reduced the food intake of pregnant rats, resulting in different rates of body weight gain during treatment (from pregnancy day 15 to day 20): F16 = 29.0 g, V80 = 28.7 g vs C = 39.5 g (median). Birth weight was influenced by treatment and sex (P<0.05; two-way ANOVA). Both doses of fluoxetine or venlafaxine reduced the body weight of litters; however, the body weight of litters from treated dams was equal to the weight of control litters by the time of weaning. At weaning there was no significant difference in weight between sexes. There was no difference among groups in number of live pups at birth, stillbirths, mortality during the lactation period or in the manifestation of serotonergic syndrome in adult rats. The occurrence of low birth weight among pups born to dams which did not show reduced food ingestion or reduction of body weight gain during treatment with lower doses of fluoxetine or venlafaxine suggests that these drugs may have a deleterious effect on prenatal development when administered during pregnancy. In addition, fluoxetine slightly but significantly affected the duration of pregnancy (about half a day), an effect not observed in the venlafaxine-treated groups.Universidade Federal FluminenseUniversidade Federal de São Paulo (UNIFESP)UNIFESPSciELOAssociação Brasileira de Divulgação CientíficaUniversidade Federal FluminenseUniversidade Federal de São Paulo (UNIFESP)Da-silva, V.a.Altenburg, S.p.Malheiros, L.r.Thomaz, T.g.Lindsey, Charles Julian [UNIFESP]2015-06-14T13:24:49Z2015-06-14T13:24:49Z1999-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion93-98application/pdfhttp://dx.doi.org/10.1590/S0100-879X1999000100014Brazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 32, n. 1, p. 93-98, 1999.10.1590/S0100-879X1999000100014S0100-879X1999000100014.pdf0100-879XS0100-879X1999000100014http://repositorio.unifesp.br/handle/11600/714WOS:000078324100014engBrazilian Journal of Medical and Biological Researchinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-29T17:11:57Zoai:repositorio.unifesp.br/:11600/714Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-07-29T17:11:57Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy
title Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy
spellingShingle Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy
Da-silva, V.a.
development
fluoxetine
venlafaxine
rats
title_short Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy
title_full Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy
title_fullStr Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy
title_full_unstemmed Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy
title_sort Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy
author Da-silva, V.a.
author_facet Da-silva, V.a.
Altenburg, S.p.
Malheiros, L.r.
Thomaz, T.g.
Lindsey, Charles Julian [UNIFESP]
author_role author
author2 Altenburg, S.p.
Malheiros, L.r.
Thomaz, T.g.
Lindsey, Charles Julian [UNIFESP]
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Universidade Federal Fluminense
Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Da-silva, V.a.
Altenburg, S.p.
Malheiros, L.r.
Thomaz, T.g.
Lindsey, Charles Julian [UNIFESP]
dc.subject.por.fl_str_mv development
fluoxetine
venlafaxine
rats
topic development
fluoxetine
venlafaxine
rats
description The aim of the present study was to compare the toxic effects of fluoxetine (F) (8 and 16 mg/kg) and venlafaxine (V) (40 and 80 mg/kg) administered during the third week of pregnancy on early development of rats. Both antidepressants were administered by gavage on pregnancy days 15 to 20 to groups of 10 to 12 animals each. Duration of gestation, food and water consumption, number of live pups and birth weight were recorded. Litters were culled to six pups at birth (day 1) and followed for growth until weaning (day 25). On day 60, a male and a female from each litter were injected with the 5-HT1 agonist, 5-methoxy-N,N-dimethyltryptamine (6 mg/kg, ip) and the serotonergic syndrome was graded. Fluoxetine but not venlafaxine reduced the duration of pregnancy when compared to the control (C) group (F = 21.1 days and C = 21.6 days, mean, P<0.02; maximum = 22 days and minimum = 21 days in both groups). The highest doses of both fluoxetine, 16 mg/kg (F16), and venlafaxine, 80 mg/kg (V80), reduced the food intake of pregnant rats, resulting in different rates of body weight gain during treatment (from pregnancy day 15 to day 20): F16 = 29.0 g, V80 = 28.7 g vs C = 39.5 g (median). Birth weight was influenced by treatment and sex (P<0.05; two-way ANOVA). Both doses of fluoxetine or venlafaxine reduced the body weight of litters; however, the body weight of litters from treated dams was equal to the weight of control litters by the time of weaning. At weaning there was no significant difference in weight between sexes. There was no difference among groups in number of live pups at birth, stillbirths, mortality during the lactation period or in the manifestation of serotonergic syndrome in adult rats. The occurrence of low birth weight among pups born to dams which did not show reduced food ingestion or reduction of body weight gain during treatment with lower doses of fluoxetine or venlafaxine suggests that these drugs may have a deleterious effect on prenatal development when administered during pregnancy. In addition, fluoxetine slightly but significantly affected the duration of pregnancy (about half a day), an effect not observed in the venlafaxine-treated groups.
publishDate 1999
dc.date.none.fl_str_mv 1999-01-01
2015-06-14T13:24:49Z
2015-06-14T13:24:49Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S0100-879X1999000100014
Brazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 32, n. 1, p. 93-98, 1999.
10.1590/S0100-879X1999000100014
S0100-879X1999000100014.pdf
0100-879X
S0100-879X1999000100014
http://repositorio.unifesp.br/handle/11600/714
WOS:000078324100014
url http://dx.doi.org/10.1590/S0100-879X1999000100014
http://repositorio.unifesp.br/handle/11600/714
identifier_str_mv Brazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 32, n. 1, p. 93-98, 1999.
10.1590/S0100-879X1999000100014
S0100-879X1999000100014.pdf
0100-879X
S0100-879X1999000100014
WOS:000078324100014
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Brazilian Journal of Medical and Biological Research
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 93-98
application/pdf
dc.publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268442080968704